New Funded Studies: Not Currently Recruiting

01. ALaCaRT

Principal Investigator: Deepa Suryanarayan

Funding: CanVECTOR Pilot

Design: Open-label pilot RCT(randomized clinical trial) comparing Apixaban and current standard of care with LMWH (low-molecular-weight heparin) for treatment of catheter-related thrombosis in patients with cancer.

04. PEITHO III

Principal Investigators: Kerstin de Wit

Co-Investigators:
Lana Castellucci and Marc Rodger (Ottawa)
Ali Mulla
Sudeep Shivakumar (Halifax)
Andrew Hirsch and Susan Kahn (Montreal)

Funding: CanVECTOR Pilot

Design: Prospective cohort study of patients on warfarin or DOAC for at least 3 months who require cessation of anticoagulation for a planned elective procedure.

05. Periop-3

Principal Investigator: Michael Kovacs

Funding: BMS Pfizer (Bristol-Myers Squibb Pfizer)

Design: Prospective observational cohort of patients on Warfarin or DOAC (Direct Oral Anticoagulant) for at least 3 months who require cessation of anticoagulation for a planned elective procedure.

06. RithMM

Principal Investigators: Martha Louzada

Funding: London Multiple Myeloma Support Group

Design: Pilot open-label RCT to compare the efficacy and safety of Rivaroxaban or ASA in preventing venous or arterial thromboembolic events in patients with myeloma on Len-Dex based therapy

For more information:NCT03428373 https://clinicaltrials.gov/

08. TILE Pilot study

Principal Investigators: Jean Philippe Galanaud, Susan Kahn;

Funding: LEO Pharma

Design: RCT comparing 3-weeks of tinzaparin then DOAC vs DOAC alone for prevention of PTS in high-risk symptomatic DVT patients (Iliac vein or common femoral vein).

09. TRIM-Line

Principal Investigators: Rick Ikesaka, Marc Carrier

Funding: CanVECTOR Pilot

Design: Pilot double-blind placebo-controlled RCT (randomized clinical trial) investigating primary thromboprophylaxis with rivaroxaban in patients with malignancy and central venous catheters.

10. Muffin PTS

Principal Investigators: Jean-Philippe Galanaud, Susan Kahn

Funding: CIHR

Design: RCT evaluating venoactive medication vs placebo for reduction in PTS